BC Companions has entered into an settlement with Goldman Sachs Asset Control to obtain a majority stake in Synthon, which focuses on the improvement and manufacturing of generic compound medication. The settlement, the volume of which exceeded 2 billion euros, considerations the sale of the bulk stake within the corporate Synthon held through BC Companions since 2019, to the funding arm of Goldman Sachs. In keeping with this settlement, BC Companions will retain an important 25% stake in Synthon following the finishing touch of the purchase. It will have to be famous that BC Companions obtained Synthon in 2019, the valuation of which amounted to 750 million. euro.
Are you a subscriber? Log in
Or check in
If you wish to see the entire model you should be a subscriber. Get a subscription lately through clicking right here
#Settlement #Goldman #Sachs #NEWS